Establishment and Characterization of a Novel Pleuropulmonary Blastoma Cell Line
- PMID: 39400393
- DOI: 10.1002/gcc.23276
Establishment and Characterization of a Novel Pleuropulmonary Blastoma Cell Line
Abstract
Purpose: Pleuropulmonary blastoma (PPB) is an infrequently encountered childhood malignant intrathoracic neoplasm associated with unfavorable clinical behavior. Since a well-characterized preclinical model is essential for developing competent agents for PPB, we aim to establish and characterize the world's first cell line of PPB, and attempt to perform the cytotoxicity assay on the PPB cell line.
Experimental design: The index case is a 2-year-old female who developed a right thoracic tumor that was surgically removed and treated with multi-agent chemotherapy. The patient is free from recurrence, although it was 9 years after the diagnosis when she developed a thyroid tumor. We performed in vitro cultivation of the isolated neoplastic cells from the tumor, cytogenetic findings and molecular analysis, and tetrazolium colorimetric assay.
Result: The histology was consistent with PPB. Serial passage of cultivation produced a continuously growing cell line, KCMC-PPB-1. Conventional cytogenetic analysis of the established cell line revealed complex numerical and structural chromosomal abnormalities, including add(17)(p11). Mutation analysis on the cultured cells revealed amino-acid substitution mutation on exon 4 of TP53 (NM_001276760.3:c.212_213delTG; NP_001263689.1:p.Leu72ArgfsTer37) and compound heterozygous mutations of DICER1 (NM_177438.3:c. 4910C>A; NP_803187.1:Ser1637* and NM_177438.3:c. 5114A>T; NP_803187.1:Glu1705Val). The cultivated cells demonstrated vulnerability to bortezomib on cytotoxicity assay.
Conclusion: Our KCMC-PPB-1 is the first genuine, molecularly characterized PPB cell line. The cell line is transplantable to nu/nu mice; therefore, it is suitable for a preclinical model for new drug development. The cytotoxicity assay demonstrated that bortezomib is active in the current PPB model.
Keywords: DICER1; bortezomib; pleuropulmonary blastoma.
© 2024 Wiley Periodicals LLC.
References
-
- L. P. Dehner, Y. H. Messinger, K. A. Schultz, G. M. Williams, K. Wikenheiser‐Brokamp, and D. A. Hill, “Pleuropulmonary Blastoma: Evolution of an Entity as an Entry Into a Familial Tumor Predisposition Syndrome,” Pediatric and Developmental Pathology 18 (2015): 504–511, https://doi.org/10.2350/15‐10‐1732‐OA.1.
-
- D. A. Hill, J. Ivanovich, J. R. Priest, et al., “DICER1 Mutations in Familial Pleuropulmonary Blastoma,” Science 325 (2009): 965, https://doi.org/10.1126/science.1174334.
-
- J. M. Taube, C. A. Griffin, R. Yonescu, et al., “Pleuropulmonary Blastoma: Cytogenetic and Spectral Karyotype Analysis,” Pediatric and Developmental Pathology 9 (2006): 453–461.
-
- M. Seki, K. Yoshida, Y. Shiraishi, et al., “Biallelic DICER1 Mutations in Sporadic Pleuropulmonary Blastoma,” Cancer Research 74 (2014): 2742–2749.
-
- T. J. Pugh, W. Yu, J. Yang, et al., “Exome Sequencing of Pleuropulmonary Blastoma Reveals Frequent Biallelic Loss of TP53 and Two Hits in DICER1 Resulting in Retention of 5p‐Derived miRNA Hairpin Loop Sequences,” Oncogene 33 (2014): 5295–5302, https://doi.org/10.1038/onc.2014.150.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials